HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Convinced: Cosmetic Adverse Event Reports Aren’t Telling Whole Story

Executive Summary

Linda Katz, director of the FDA’s cosmetics office, says to “stay tuned” for federal legislative developments in 2022, maintaining her position that voluntary adverse-event reporting paints an incomplete picture of consumers’ experience with cosmetic products across the US.

You may also be interested in...



ICCR-15: International Cosmetics Regulator Group Tackles Consumer Safety Perceptions

The International Cooperation on Cosmetics Regulations continues efforts to minimize barriers to international trade through regulatory convergence, while also taking steps to educate consumers on cosmetics safety issues that may be widely misunderstood. Personal Care Products Council leadership discusses developments from the regulator group’s 15th annual meeting in June.

US Cosmetics Reform Bill Would Require FDA Regulation Of ‘Natural’ Labeling

Beautycounter and Burt’s Bees are among the most vocal companies pushing for modernization of US cosmetics regulations via the proposed Personal Care Products Safety Act, which would require the FDA to establish a “natural” definition for use in product labeling.

FDA Cosmetics Director: ‘Sporadic’ WEN AERs Make Case For Mandatory Reporting

In a Q&A posting, FDA Office of Cosmetics and Colors Director Linda Katz offered perspective on how the division handles adverse event reports and makes a case for mandatory AE reporting. She also explains how FDA reacted when WEN-related AERs began rolling in.

Related Content

Topics

UsernamePublicRestriction

Register

RS151936

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel